Vectus Biosystems Limited (VBS) AI Stock Analysis

• Market Cap: AU$2.56M
• Dividend Yield: N/A
• Average Volume (3M): 49.78K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.69
• Revenue Growth: N/A
• EPS Growth: 9.19%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 53,278,313
• 10 Day Avg. Volume: 70,112
• 30 Day Avg. Volume: 49,777
• PEG Ratio: 0.15
• Price to Book (P/B): 5.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: AU$0.00 ▼(-100.00%Downside)

Vectus Biosystems Limited shows significant financial and market challenges. The weak financial performance and bearish technical indicators are the most significant factors influencing the low stock score. The negative valuation metrics further contribute to the overall assessment. Immediate strategic improvements are necessary to enhance investor confidence.

Vectus Biosystems Limited Business Overview & Revenue Model

Company Description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.

How the Company Makes Money

Vectus Biosystems Limited makes money primarily through the development and commercialization of its pharmaceutical products aimed at treating fibrotic diseases and hypertension. The company's revenue model includes licensing agreements with larger pharmaceutical companies for its drug candidates, securing milestone payments upon reaching specific development stages, and receiving royalties on product sales once the drugs are marketed. Additionally, Vectus may engage in collaborative research and development partnerships, which can provide financial support and share the risk of drug development. The company's financial success is significantly influenced by the progress of its drug candidates through clinical trials and regulatory approvals, as well as the potential for successful commercialization of its products.

Vectus Biosystems Limited Financial Statement Overview

Summary

Vectus Biosystems Limited is facing significant financial challenges, with declining revenues, persistent losses, and negative equity. Despite some improvement in cash flow, the overall financial health remains weak, requiring strategic initiatives to enhance revenue and manage costs.

Income Statement

Vectus Biosystems Limited has demonstrated a declining revenue trend with a negative revenue growth rate from 2023 to 2024. The company is struggling with profitability, reflected in negative net profit and EBIT margins. Despite some gross profit, the overall financial performance remains weak due to high operating losses.

Balance Sheet

The balance sheet shows a significant improvement in debt levels, but the company still faces challenges with negative equity, indicating long-term financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio remains negative, undermining financial stability.

Cash Flow

The cash flow statement highlights negative operating and free cash flows, with slight improvement in free cash flow from the previous year. The company exhibits a weak operating cash flow to net income ratio, indicating inefficient cash conversion from operations.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
884.21K	1.14M	1.35M	1.30M	180.00	51.19K
	Gross Profit
884.21K	1.14M	1.31M	1.28M	1.02M	31.67K
	EBIT
-2.14M	-2.27M	-4.60M	-4.60M	-3.80M	-2.71M
	EBITDA
-2.14M	-2.27M	-3.19M	-3.28M	-3.71M	-2.64M
	Net Income Common Stockholders
-2.26M	-2.34M	-3.45M	-3.99M	-3.86M	-3.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
809.89K	808.97K	2.95M	1.28M	5.78M	2.72M
	Total Assets
1.23M	2.03M	4.63M	3.94M	6.98M	3.00M
	Total Debt
0.00	28.93K	70.21K	6.90M	8.68M	8.28M
	Net Debt
-809.89K	-780.04K	-2.88M	5.62M	2.90M	5.60M
	Total Liabilities
830.77K	539.26K	1.11M	8.36M	9.88M	9.71M
	Stockholders Equity
403.15K	1.49M	3.52M	-4.42M	-2.90M	-6.71M
Cash Flow		Free Cash Flow
-1.41M	-2.10M	-2.37M	-4.46M	-3.26M	-3.00M
	Operating Cash Flow
-1.44M	-2.03M	-2.35M	-4.44M	-3.26M	-3.00M
	Investing Cash Flow
268.04K	-67.90K	-17.13K	-21.00K	0.00	0.00
	Financing Cash Flow
-41.28K	-41.28K	4.04M	-34.55K	6.35M	5.64M

Vectus Biosystems Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 34.58 is Neutral, neither overbought nor oversold. The STOCH value of 51.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
VBS	38 Underperform	AU$2.56M	―	-163.00%	―	―	9.19%
BITRF		$1.72M	―	-119.28%	―	―	―
PBIGF		$75.73M	―	-46.65%	―	―	―
PRRUF		$255.60M	―	-31.16%	―	―	―
PTX	56 Neutral	AU$42.68M	―	-36.95%	―	―	11.11%
MVP	47 Neutral	AU$64.78M	―	-45.40%	―	13.61%	-55.12%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Advances VB0004 Commercialization and Seeks Chinese Collaborations

Vectus Biosystems Limited has been actively advancing its commercialization efforts for its lead compound, VB0004, and other drug candidates, with a focus on potential collaborations in China. The company has validated VB0004’s safety profile in recent clinical trials and is exploring faster approval paths in China. Financially, Vectus has reduced operating costs and is seeking licensing opportunities to support further clinical studies, with cash-on-hand reported at $370,000 as of March 2025.